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Abstract: The efﬁ  cacy of tamsulosin at the cost of a relatively benign side effect proﬁ  le has 
been attributed to receptor selectivity directed at the α1a and α1d adrenergic receptor subtypes. 
The oral-controlled absorption system (OCAS®) represents a drug delivery reﬁ  nement that 
incorporates a matrix of gel-forming and gel-enhancing agents to promote a constant drug release 
independent of environmental food or ﬂ  uid. There are clinical data to support the concept that 
drug peaks are lessened and that drug release continues throughout the alimentary tract due to 
the OCAS formulation. Furthermore this equates with less adverse effects on physiologic param-
eters. To date however improvements in cardiovascular symptoms such as dizziness, headache 
and syncope have not been demonstrated in healthy men. Ejaculatory dysfunction appears less 
problematic with the OCAS preparation. Tamsulosin OCAS may be of greatest beneﬁ  t to men 
with cardiovascular co-morbidities taking anti-hypertensive medications that might predispose 
them to symptomatic hypotensive episodes. It will be necessary to evaluate this group of men 
more closely in further trials to determine what they stand to gain from changing medications, 
and then relate this to drug costs to draw a ﬁ  nal conclusion as to the place of tamsulosin OCAS 
in contemporary urological practice.
Keywords: lower urinary tract symptoms, benign prostatic hyperplasia, tamsulosin OCAS, 
safety, efﬁ  cacy, tolerability
Introduction
Lower urinary tract symptoms (LUTS) are an increasing quality of life issue for many 
men as they age. Roughly one quarter of men over the age of 45 are effected by LUTS 
as deﬁ  ned by an International Prostate Symptom Score (IPSS) greater than 7, and the 
prevalence in men over the age of 70 is closer to 40% (Andersson et al 2004).
The approach to treatment of these symptoms has always been grounded in the 
analysis of risk versus beneﬁ  t for the individual. Historically symptoms have been 
managed by conservative measures such as ﬂ  uid intake modiﬁ  cation or poorly sub-
stantiated remedies from the general consciousness until symptoms progressed to the 
point where the risks of surgery were considered acceptable to achieve the beneﬁ  ts 
of symptom relief. Many men tolerated profound difﬁ  culties for fear of the surgeon’s 
blade. This has been revolutionized by the development of effective medical therapy. 
Medical treatment for LUTS attributed to benign prostatic hyperplasia (BPH) has now 
become the mainstay of treatment due to the non-invasive nature and reversibility it 
offers. Surgical intervention is now generally reserved for progressive disease or fail-
ures of medical therapy. Current thought holds that lower urinary tract symptoms arise 
at least in part from outﬂ  ow tract obstruction. This then provokes physiological and 
behavioral changes in bladder function. Outﬂ  ow obstruction is considered as the sum 
of two contributing parts, one dynamic and one static. Medical therapy has evolved to 
address both contributory components with α adrenergic receptor antagonists used as Therapeutics and Clinical Risk Management 2008:4(1) 12
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primary treatment for the former and 5 α reductase inhibitors 
used for the latter. The α adrenergic receptor antagonists 
work primarily by reducing smooth muscle tone in the blad-
der neck and prostate whereas 5 α reductase inhibitors induce 
epithelial atrophy (Gup et al 1990; Lepor 1990; Gormley 
et al 1992). A combination of the two has been shown to be 
superior to either alone in achieving long-term prevention 
of disease progression; however, it is clear that reduction of 
prostate volume is not always required to achieve improve-
ments in symptomatology (McConnell et al 2003).
For the great majority of men, BPH is a disease of symp-
toms rather than complications and therefore any medical 
treatment for this condition must achieve symptom relief with 
minimal toxicity. Although α blockers have been regarded 
as an effective therapy option for some time, they are not 
without side effects (Roehrborn and Siegel 1996). Recently 
attempts have been made to improve the therapeutic window 
of these agents with modiﬁ  cations aimed at increasing recep-
tor selectivity and optimizing drug delivery. This article is 
intended to review the role of tamsulosin oral-controlled 
absorption system (OCAS®). This represents a novel drug 
delivery system for the α1-adrenergic receptor speciﬁ  c tam-
sulosin, in the treatment of LUTS related to BPH.
Tamsulosin
It was recognized as early as the mid 1970s that subgroups 
of α adrenergic receptors exist (Langer 1974). Phenoxyben-
zamine, the original non-selective α receptor antagonist used 
for the treatment of LUTS, induced signiﬁ  cant side effects 
such as fatigue, impaired ejaculation, nasal congestion, diz-
ziness, and hypotension. The discovery of an abundance of 
the α1 receptor subgroup in the bladder neck and prostatic 
smooth muscle, coupled with the need to avoid these side 
effects, drove research into the concept of uroselectivity in 
which reﬁ  nement of receptor stimulation reduces collateral 
side effects (Lepor et al 1988). Prazosin, the ﬁ  rst α1 selective 
agent, demonstrated comparable efﬁ  cacy with improved 
tolerability by comparison with phenoxybenzamine. Longer-
acting α1 selective medications followed shortly thereafter. 
Among these was tamsulosin, the ﬁ  rst α1 subtype selective 
antagonist. The α1a and to a lesser extent α1d receptors pre-
dominate in urologic tissues, whereas α1b receptors are found 
more commonly in the cardiopulmonary, splenic, renal, and 
vascular tissues (Roehrborn and Schwinn 2004). Tamsulosin 
has a roughly 10 times higher afﬁ  nity for the α1a than the α1b 
receptor (Kenny et al 1996).
Phase III randomized placebo controlled trials have dem-
onstrated clinically signiﬁ  cant improvements in symptom 
scores and peak ﬂ  ow rates at both 0.4 mg and 0.8 mg doses 
of tamsulosin (Lepor 1998; Narayan and Tewari 1998). Sub-
sequently a systematic review of clinical trials has reached 
similar conclusions (Wilt et al 2002). The weighted mean 
difference in change from baseline symptom score for tamsu-
losin (0.4 mg) over placebo was 12% and the weighted mean 
difference in change from baseline peak urinary ﬂ  ow rate 
for tamsulosin (0.4 mg) over placebo was 1.05 mL/s (95% 
CI 0.59–1.51) (selected trials are summarized in Table 1). 
Overall there was a 5% adverse event related withdrawal rate 
on the 0.4 mg dose schedule. The predominant side effects 
were dizziness, rhinitis, abnormal ejaculation, and headache, 
each of which occurred in 6%–10% of participants (Table 2). 
The Cochrane Database review of 2003 stated that tamsu-
losin provided moderate beneﬁ  ts in urinary symptoms and 
ﬂ  ow rate compared with placebo at a level similar to other 
alpha antagonists (Wilt et al 2003). Additionally there were 
minimal improvements in symptomatology but substantial 
increases in side effects when the dose of tamsulosin was 
increased from 0.4 mg to 0.8 mg.
A multicenter extension trial involving participants from 
three shorter double blind placebo-controlled studies was pub-
lished in 2003 (Narayan et al 2003). Of the 609 men recruited, 
109 completed the 6-year follow-up (as only 159 men had 
Table 1 Selected randomized placebo controlled trials of tamsulosin (0.4 mg) assessing symptom scores (recorded as the percent-
age change between mean baseline and mean achieved symptom scores) and maximal ﬂ  ow rates (recorded as the percentage change 
between mean baseline and mean achieved peak ﬂ  ow in milliliters per second)
Reference  Number  Duration  % change in     p value  % change in mean   p value
     symptom  score    peak  ﬂ  ow (mL/s)
      tamsulosin placebo    tamsulosin placebo 
Abrahms et al 1997  126  14/52  −29  −18 0.002 22  −1 0.03
Chapple et al 1996  575  14/52  −35  −26 N.S.  16  6  0.002
Lepor et al 1998  756  17/52  −41  −28   0.001 24  9   0.001
Narayan and Tewari 2003  735  17/52  −27  −19 0.01  15  9  NSa
aNot signiﬁ  cant.Therapeutics and Clinical Risk Management 2008:4(1) 13
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received 2 years or more of treatment prior to entry). A 25% 
or greater decrease in AUA score was preserved for up to 80% 
of men and a 30% or better improvement in maximal ﬂ  ow 
rate was sustained for up to 40% of men. Fifteen percent of 
patients discontinued tamsulosin due to side effects, including 
0.2% each for postural hypotension and syncope. This study 
indicates that the early efﬁ  cacy and tolerability of tamsulosin 
continues beyond 5 years for most men.
How can we improve on tamsulosin in the treatment of 
BPH related LUTS? Symptom control increases somewhat 
with dose escalation; however, the cost in terms of side 
effects is disproportionate (Wilt et al 2002). The concept of 
prolonging the optimal serum drug level to achieve a longer 
effect for each dose taken is an appealing one. Theoretically 
it might also dampen adverse events resulting from rapid 
drug peaks soon after ingestion. The mode of drug delivery 
therefore presents a target for reﬁ  nement.
The conventional modiﬁ  ed release (MR) formulation of tam-
sulosin has a variable absorption proﬁ  le dependent on when it is 
taken in relation to food and gastrointestinal transit time. As such 
if 0.4 mg is taken on an empty stomach it results in a roughly 
70% higher serum level than if taken after a meal (Lyseng-
Williamson et al 2002). Taking tamsulosin in the fasting state 
increases the risk of unwanted cardiovascular effects such as 
orthostatic hypotension, dizziness, headache, and syncope 
(Michel et al 2005a). Additionally the multi-coated membrane 
of the pellet releases drug only in the presence of water which 
is progressively less available along the alimentary canal. This 
results in the release of drug largely in the stomach and small 
intestine rather than the colon (Chapple and Chartier-Kastler 
2006). These drawbacks in combination lead to suboptimal 
serum drug levels over the 24-hour dosing interval which may 
correlate with poorer symptom control, and a reliance on patient 
compliance with respect to timing to lessen side effects.
Tamsulosin oral controlled 
absorption system
Repackaging tamsulosin in the OCAS formulation arose 
from a desire to extend drug release over a longer period of 
time. Optimal serum and tissue drug levels might be expected 
to lead to a subsequent improvement in symptom control, 
especially overnight. The OCAS construct uses gel-forming 
and gel-enhancing agents to overcome the continual depen-
dence of previous drug delivery systems on water to enable 
chemical release. The matrix hydrates rapidly in the stomach 
and thereafter is no longer dependent on environmental 
water for drug release. It is also resistant to changes in pH 
and gastrointestinal motility (Sako et al 1996). Theoretically 
this system should decrease food effect and reduce peak to 
trough serum drug ﬂ  uctuations, maintaining concentrations 
above the minimum effective level for longer and blunting 
the degree and rapidity of maximal levels.
Randomized phase one studies have been conducted to 
determine whether this in fact is the case (Michel et al 2005a). 
In each, healthy volunteers between the ages of 19 and 44 
were given tamsulosin OCAS, and serum levels assessed 
before then and at intervals after dosing to determine the 
pharmacokinetic proﬁ  le.
The ﬁ  rst study compared 0.4 mg tamsulosin MR in the 
fed state with 0.4 mg tamsulosin OCAS in the fasted state 
(Michel et al 2005b). The maximal serum concentration 
achieved (Cmax) and peak to trough variations (expressed 
as maximal concentration divided by the concentration at 
24 hours (C24hr) were reduced in the OCAS group. Effects 
on time to maximal concentration and the elimination half-
life of the drug were similar with each formulation however 
the area under the curve for the 24-hour period was slightly 
less with the OCAS preparation. The trade-off between the 
preparations for steadier drug delivery and avoidance of food 
effect is a somewhat lower total amount of drug absorbed 
for the same dose administered (Table 3).
Table 2 Adverse event proﬁ  le summarized from multiple ran-
domized controlled trials (derived from Wilt et al 2002)
Adverse event  Tamsulosin  Placebo  Relative riska
Withdrawal – all cause  12.2%  12%  1.02 (0.80–1.30)
Withdrawal – due to   7.2%  6.7%  1.08 (0.72–1.62)
adverse event
Headache 14.3%  14.6%  1.00  (0.81–1.23)
Dizziness 11.9%  7.8%  1.50  (1.13–1.98)
Rhinitis 11.2%  6%  1.84  (1.24–2.72)
Abnormal ejaculation  10.8%   1% 17.0  (2.5–114.2)
Asthenia 6%  4.3%  1.33  (0.89–1.97)
Any adverse event  53.5%  51.3%  1.07 (0.72–1.62)
aRelative risk is expressed as the calculated value with 95% conﬁ  dence intervals in 
parentheses.
Table 3 Pharmacokinetic outcomes of the randomized compari-
son of 0.4 mg of tamsulosin in modiﬁ  ed release (MR) form in the 
fed state with oral-controlled absorption system (OCAS) form 
in the fasting state (derived from data of Wilt et al 2002)
Variable Tamsulosin    Tamsulosin 
  MR 0.4 mg  OCAS 0.4 mg
Cmax (ng/mL)  13.74  5.88
Tmax (h)  6.67  8.51
T1/2 (h)  16.13  18.67
AUC (ng.h/mL)  253.7  175.7Therapeutics and Clinical Risk Management 2008:4(1) 14
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The second study looked at tamsulosin 0.4 mg, 0.8 mg, 
and 1.2 mg doses and the effect of food on drug delivery 
(Wilt et al 2002). No difference was observed in relation to 
serum drug levels dependent on whether volunteers were fed 
or not at the time of drug administration. Increasing doses led 
to increased Cmax and AUC but not Tmax or T1/2. The authors 
concluded that OCAS delivery resulted in a more favorable 
pharmacokinetic proﬁ  le than MR delivery and was indepen-
dent of food consumption.
Further studies using scintigraphically measured techne-
tium-99m labeled tamsulosin OCAS release have conﬁ  rmed 
continuous drug release throughout the entire alimentary 
tract, independent of regional transit times (Stevens and 
Speakman 2006).
Efﬁ  cacy of tamsulosin OCAS
Demonstration of a favorable pharmacokinetic proﬁ  le in 
phase I studies allowed progression to phase II and III trials 
to evaluate whether improvements in efﬁ  cacy would follow 
(Chapple et al 2005a, b; Djavan et al 2005).
Chapple et al (2005a) published a study of 839 men 
45 years of age or older with International Prostate Symp-
tom Scores (IPSS) greater than 12, in which subjects were 
randomized to tamsulosin OCAS 0.4 mg, 0.8 mg, or 1.2 mg 
doses or placebo. All doses of tamsulosin OCAS reached 
statistical signiﬁ  cance for improvement in total IPSS (of 
 25%) and in the IPSS quality of life question alone over 
placebo (Table 4). There was a 10% increase from 63% 
(placebo) to 73% (0.4 mg dose) in the number of men treated 
who had a response in IPSS. Whether this is clinically sig-
niﬁ  cant is open to debate. The study did demonstrate that 
although there was no clear treatment beneﬁ  t with doses 
higher than 0.4 mg, there was a clear increase in treatment-
related adverse effects and thereby established the optimal 
treatment dose.
A further phase III trial involving 2152 men com-
pared the symptomatic response to placebo, tamsulosin 
MR 0.4 mg, tamsulosin OCAS 0.4 mg, or 0.8 mg (Chapple 
et al 2005b). Findings were similar to the abovementioned 
trial in terms of relative improvements from the tamsulosin 
OCAS 0.4 mg and 0.8 mg doses (Table 5). Adverse events 
were similar for each as well. Of particular interest are 
the almost identical response and side effect proﬁ  les of 
the OCAS and MR delivery systems at the 0.4 mg dose. The 
authors commented that the adverse event rates probably 
under estimate the real life clinical situation regarding the 
MR formulation. They suggested that compliance with drug 
dosing in relation particularly to food consumption in the 
trial was much higher than might be expected in general 
practice and also pointed out that those with signiﬁ  cant 
cardiovascular co-morbidities were excluded by the trial 
protocol.
It seems increasingly clear that relief of storage symptoms 
has a more profound effect on overall quality of life than relief 
of voiding symptoms. Nocturia, being woken by the need to 
void, appears particularly bothersome for many men as loss 
of sleep may be reﬂ  ected in daytime sleepiness, impaired 
reaction time and mood change (Stanley 2005). Improving 
sleep duration and quality is certainly a reasonable goal of 
BPH-related LUTS treatment and in an attempt to address 
this a randomized, placebo-controlled trial involving 117 men 
looked at hours of undisturbed sleep (HUS) as an outcome 
variable (Djavan et al 2005). The results of this ambitious 
study are presented in Table 6, but essentially the authors 
confirmed symptomatic improvements with tamsulosin 
OCAS over placebo in line with previous studies. There 
were no signiﬁ  cant differences in the number of nocturia 
events or minutes of undisturbed sleep. The study is most 
interesting for its attempt to quantify the beneﬁ  t of medi-
cal therapy of LUTS on sleep and represents a pioneering 
foray into this ﬁ  eld, worthy of future reﬁ  nement. It does not 
however provide evidence to support the superior efﬁ  cacy 
of the OCAS formulation over other drug delivery systems 
for this purpose.
Table 4 Symptomatic response and adverse event rates in men on various doses of tamsulosin oral-controlled absorption system or 
placebo (derived from data of Chapple et al 2005a)
  Placebo  0.4 mg  0.8 mg  1.2 mg
Number of subjects  211  203  206  210
Percent with reduction in IPSS  25% 63%  73%  80%  77%
P value (treatment vs. placebo)    0.02   0.01 0.02
Change in IPSS QoL score  −0.9  −1.3  −1.4  −1.4
P value (treatment vs placebo)    0.0005   0.0001   0.0001
Adverse events  26%  29%  30%  36%
Abbreviations: ICSS, International Prostate Symptom Score.Therapeutics and Clinical Risk Management 2008:4(1) 15
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Cardiovascular safety of tamsulosin 
OCAS
Blockade of α1 adrenergic receptors with antagonists allows 
smooth muscle relaxation in the prostate, bladder neck, and 
urethra; however, inhibition of the same receptors in vascular 
smooth muscle leads to vasodilatation and lower blood pres-
sure. In most men this is of no consequence, in some it may 
induce symptomatic results such as dizziness, headache, and 
syncope. As a large number of men requiring treatment for 
BPH-related LUTS are elderly with cardiovascular comor-
bities and frequently on medications with antihypertensive 
effects they represent the highest risk group for α blocker 
induced cardiovascular side effects. Normal functional 
reserves may be further compromised by times of relative 
cardiovascular stress such as heavy meals, exercise, hot 
conditions, and dehydration (Barendrecht et al 2005).
Using phenylephrine an α1 adrenergic receptor agonist, 
Michel et al (2005c) attempted to determine the likelihood 
that tamsulosin OCAS would cause adverse cardiovascular 
events. They reasoned that the more phenylephrine required 
to increase diastolic blood pressure (dBP) and total peripheral 
resistance (TPR), the greater effect the α1 adrenergic recep-
tor agonist is having on the peripheral vasculature and 
therefore the more likely it is to cause cardiovascular side 
effects at times of limited reserve. This study used 18 healthy 
men younger than 45 years of age as subjects for a 3-way 
crossover study that compared placebo with the tamsulosin 
OCAS and MR formulations. In order to anticipate real world 
non-compliance with dosing instructions (which suggest that 
the MR form should be taken after breakfast) the drugs were 
given in the fasting state. Phenylephrine induced changes in 
dBP and TPR were measured 2 hours prior to, then every 
2 hours after, dosing over a 10-hour period. There was less 
inhibition of phenylephrine induced changes in dBP and 
TPR with the post dose OCAS formulation than seen with 
the MR formulation and this was statistically signiﬁ  cant in 
all except the initial 2-hour post-dose interval. The authors 
interpreted these statistical changes in physiological param-
eters to represent a better cardiovascular safety proﬁ  le for 
the former preparation.
To assess the clinical relevance of these ﬁ  ndings, the 
same authors measured the effects of the two formulations 
on 40 healthy older ( 60 years old) men using orthostatic 
stress testing (Michel et al 2005d). This involved subjects 
lying down for 5 minutes, then sitting for 2 minutes, and 
ﬁ  nally standing for 3 minutes while non-invasive pulse and 
blood pressure measurements were conducted at 2-hourly 
intervals over 10 hours following dosing in the fasted state. 
Positivity was indicated by one or more of (1) symptoms 
(eg, dizziness, light-headedness), (2) a decrease in sBP  20 
mmHg, (3) a decrease of dBP  10 mmHg or a standing dBP 
 60 mmHg, (4) an increase in pulse rate  20 beats/minute 
or a standing pulse rate  100 beats/minute. The OCAS 
formulation had a cumulative incidence of positive tests of 
17.5% compared with 31.7% for the MR formulation with 
Table 5 Symptomatic responses and adverse event rates in men on placebo, tamsulosin oral-controlled absorption system (OCAS) 
or modiﬁ  ed release (MR) drug delivery systems (derived from data of Chapple et al 2005b)
  Placebo  OCAS 0.4 mg  OCAS 0.8 mg  MR 0.4 mg
Number 350  354  707  700
Percent with reduction in IPSS  25% 60.9%  71.2%  75.4%  73.8%
Change from baseline IPSS  −3.7  −4.7  −5.0  −5.0
P value (treatment vs placebo)     0.001    0.001
P value (treatment vs MR 0.4 mg)      NSa
Change in IPSS QoL score  −2.2  −3.0  −3.0  −3.0
P value (treatment vs placebo)     0.001    0.001
P value (treatment vs MR 0.4 mg)      NS 
Adverse events  3.7%  6.9%  11.1%  7.8%
anot signiﬁ  cant.
Abbreviations: ICSS, International Prostate Symptom Score.
Table 6 Symptomatic responses and sleep change with tamsulo-
sin oral-controlled absorption system (OCAS) 0.4 mg compared 
with placebo (derived from data of Chapple et al 2005b).
  Placebo  Tamsulosin   p value
   OCAS  0.4  mg
Baseline IPSS  18.1  18.2  NSa
Change in IPSS  −5.6  −8.0   0.01
Change in nocturia  −0.7  −1 0.09
Change in HUS  60 minutes   81 minutes   0.20
anot signiﬁ  cant.
Abbreviations: HUS, hours of undisturbed sleep; ICSS, International Prostate 
Symptom Score.Therapeutics and Clinical Risk Management 2008:4(1) 16
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the greatest difference being at 4 hours post dose (difference 
of 20%). At each time point there were fewer positive tests 
in the OCAS arm and the results were statistically signiﬁ  -
cant. Although there was little difference between the two 
preparations in terms of symptomatic adverse events (17.5% 
with OCAS, 22.5% with MR), the authors stressed that the 
trial subjects were healthy and that these results would likely 
underestimate differences for the general population at higher 
risk of cardiovascular adverse events.
The same principles were applied to a further trial com-
paring 0.4 mg tamsulosin OCAS with 10 mg alfuzosin XL 
(Michel and Chapple 2006). In this two-part study, the above 
methods were again applied. Phenylephrine was adminis-
tered to 18 healthy young ( 45 years old) volunteers and 
orthostatic stress testing was conducted on 40 healthy older 
men ( 60 years old). There were statistically signiﬁ  cant 
reductions in phenylephrine inhibition favoring tamsulosin 
OCAS at the 2- and 4-hour dose intervals. The proportion of 
positive orthostatic tests was higher in the alfuzosin group 
overall (17.5% vs 5%) and at each time interval with the 
greatest difference (17.5%) at the 6-hour post-dose interval. 
Almost all differences were demonstrated in changes in 
blood pressure with pulse rate and symptomatic events being 
comparable between the two drugs.
Taken together these studies indicate that the OCAS form 
of tamsulosin shows less inhibition of vascular α1 adrenergic 
receptors than tamsulosin MR or alfuzosin XL and that this 
translates into a modest reduction in disruption of cardiovas-
cular physiological response measures to exercise in healthy 
volunteers. The previously mentioned phase III of over 2000 
men did not show a signiﬁ  cant difference in blood pressure 
changes or symptoms attributable to cardiovascular conse-
quences, between tamsulosin OCAS and placebo (Stanley 
2005). However, the trial was not designed or powered to 
evaluate differences in adverse events between the groups. 
Whether the ﬁ  ndings from these trials may be extrapolated 
to the general patient group at higher risk of such sequelae 
with treatment is open to speculation, as to date this has not 
been assessed.
Tolerability of tamsulosin OCAS
Generally speaking factors affecting the tolerability of tamsu-
losin may be considered in two broad categories, one related 
to cardiovascular function, the other to sexual function. The 
α1 adrenergic receptor antagonists as a class appear to lack 
major effects on sexual desire and reports of their effects 
on erectile function have been mixed (van Dijk et al 2006). 
Ejaculatory dysfunction, however, has been more clearly 
demonstrated in a number of randomized controlled trials 
(van Dijk et al 2006). Within the drug class, numerically 
higher incidences have been seen with tamsulosin com-
pared with other α1 blockers, although in most studies this 
has failed to achieve statistical signiﬁ  cance (Narayan et al 
2005; Nordling 2005). As it has been estimated that more 
than half of men over 60 years of age have some abnormality 
of ejaculatory function, the relevance of this cluster of side 
effects is perhaps less than that of cardiovascular adverse 
events (Frankel et al 1998).
The primary objective of the phase III trial of tamsulosin 
OCAS was to evaluate treatment effect on LUTS, as such the 
study detailed adverse effects with descriptive statistics only 
(Table 7). The exception to this was an analysis of the two 
most commonly reported adverse events, abnormal ejacula-
tion and dizziness. In this, ejaculatory dysfunction was seen 
statistically more frequently in the tamsulosin MR 0.4 mg 
group than placebo (p = 0.014) but there was no difference 
Table 7 Adverse events with tamsulosin in varying formats and doses as reported by Chapple et al (2005b)
  Placebo  OCAS 0.4 mg  OCAS 0.8 mg  MR 0.4 mg
Number 350  354  707  700
One or more adverse events  20%  26%  27%  24%
One or more treatment related adverse events  7%  11%  14%  12%
Cardiovascular events  2.2%  2.5%  3.9%  3.2%
Dizziness 1.4%  1.4%  2.4%  1.3%
Abnormal ejaculation  0.3%  1.9%  5.3%  3.1%
Number with CVS information  340  344  690  691
Change in mean sBPa on standing  −1.5  −2.2  −3.5  −3.5
Change in mean dBP on standing  −1.2  −0.5  −2.1  −2.2
Discontinuation due to adverse events  0.6%  1.9%  2.4%  1.3%
ablood pressure changes are orthostatic, measured on standing in mmHg with changes between baseline and at 12 weeks.
Abbreviations: dBP, diastolic blood pressure; sBP, systolic blood pressure; CVS, cardiovascular system.Therapeutics and Clinical Risk Management 2008:4(1) 17
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between placebo and the tamsulosin OCAS 0.4 mg group 
(p value not stated). The two formulations at the 0.4 mg dose 
were not compared with direct statistical analysis. Given that 
the absolute difference in adverse events was only 1.2%, this 
may not have reached statistical signiﬁ  cance and is unlikely 
to represent a clinically signiﬁ  cant ﬁ  nding.
Overall the incidence of adverse event related treatment 
withdrawals has been low, in the order of 2% or less, in each 
of the trials described previously. As a consequence both the 
oral controlled absorption system and modiﬁ  ed release for-
mulations may be considered to be well tolerated. The 0.4 mg 
dose in the OCAS preparation appears preferable to higher 
doses, given little difference in efﬁ  cacy but a dose-response-
related increase in adverse events, as demonstrated in the 
previously described phase II trial (Chapple et al 2005a).
Conclusions
Medical therapy is now established as the ﬁ  rst-line treatment 
for uncomplicated BPH related lower urinary tract symptoms 
and this currently includes either an α1 adrenergic receptor 
antagonist, a 5 α reductase inhibitor or a combination of both. 
Among the α blockers, tamsulosin has demonstrated efﬁ  cacy 
in a number of randomized trials with some improvement 
in its relative side effect proﬁ  le. This has been attributed to 
receptor selectivity directed at the α1a and α1d subtypes. Modi-
ﬁ  cations in drug delivery such as with the OCAS have been 
sought to avoid the effects of food on drug serum peaks and 
therefore side effects and to prolong drug release regardless 
of gastrointestinal transit. This in turn may increase the length 
of time for which symptoms are better controlled.
Data to date support the concept that drug peaks are less-
ened and that drug continues to be released once it has passed 
into the colon despite a relative lack of water in this area. 
The 0.4 mg dose provides the most desirable therapeutic risk: 
beneﬁ  t ratio. The current evidence suggests that the OCAS 
formulation is no worse than the MR formulation in achieving 
symptom control; however, the hoped-for improvements in 
nocturia control have not eventuated in clinical trials so far. 
In terms of side effects, physiologic parameters measured 
during orthostatic stress tests are less adversely affected by 
the OCAS formulation than the MR formulation taken in the 
fasting state and in comparison to alfuzosin XL 10 mg. This 
did not, however, translate into signiﬁ  cant differences in 
cardiovascular side effects for healthy men taking the drugs. 
Ejaculatory dysfunction appears less likely with the OCAS 
preparation than the MR preparation of tamsulosin.
The role of tamsulosin OCAS in the treatment of BPH 
related LUTS is in evolution. For otherwise healthy men the 
beneﬁ  ts in terms of efﬁ  cacy over the MR formulation appear 
negligible and the beneﬁ  ts in terms of side effects are mod-
est. The drug delivery system places less importance on dose 
timing, reducing the importance of patient compliance in this 
regard. The OCAS formulation may be of greatest importance 
to those men with multiple medical and particularly cardio-
vascular co-morbidities taking anti-hypertensive medications 
that might predispose them to symptomatic hypotensive 
episodes. It will be necessary to evaluate this group of men 
more closely in further trials to determine what they stand to 
gain from changing medications, and relate this to drug costs 
before drawing a ﬁ  nal conclusion as to the role of tamsulosin 
OCAS in contemporary urological practice.
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